UNSPSC 51283608: Rifamycin b diethylamide

This classification denotes an antitubercular agent with the molecular formula C43H58N2O13, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TS121H7U7E, chemically known as rifamycin, 4-o-(2-(diethylamino)-2-oxoethyl)-, but more generally known as rifamycin b diethylamide, which bears US NIH Compound Identifier 5382104. European Medicines Agency schedules rifamycin b diethylamide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10310MIG.

Most nations, for tariff purposes, schedule rifamycin b diethylamide under HS 29419000. SMILES: CCN(CC)C(=O)COC1CC2C(C3C1C4C(C(C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]([C@H](/C=C/C=C(\C(=O)N2)/C)C)O)C)O)C)OC(=O)C)C)OC)C)O.

UNSPSC 51283608 Rifamycin b diethylamide is a Commodity code under which state and local governments procure pharmaceutical products, though the recent opportunities block shows minimal activity directly aligned with the code's nominal scope. The two posted opportunities name different active ingredients—Doxycycline Hyclate, Ciprofloxacin Hydrochloride, and Naloxone—none of which are rifamycin b diethylamide. State and local health departments and county public health agencies are the primary issuing bodies under this family, sourcing pharmaceuticals through cooperative purchasing vehicles such as MMCAP Infuse and direct competitive procurement for emergency response and community health programs. Procurements typically include fixed-price supply contracts with multi-year terms and renewal options, quarterly or as-needed delivery, and standard compliance requirements such as E-Verify and drug-free workplace certification.

The Illinois Department of Public Health and Seminole County, Florida represent the recent issuing bodies, though neither opportunity directly solicited rifamycin b diethylamide. The Illinois award through MMCAP Infuse to Chartwell Rx LLC covered Doxycycline Hyclate and Ciprofloxacin Hydrochloride under an IFB process with a $2,999,999.11 total contract value over three years (awarded August 28, 2026). Seminole County issued an IFB on June 30, 2026 (due July 26, 2026) seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option. The code shows activity concentrated in the Southeast and Midwest, though the mismatch between the code's stated commodity and the active ingredients in recent solicitations suggests either data-tagging inconsistency or minimal recent procurement specifically for rifamycin b diethylamide through state and local channels.